


CDK6/9-IN-1

| | |
|--------------------|---|
| Cat. No.: | HY-131063 |
| CAS No.: | 2414373-55-8 |
| Molecular Formula: | C ₂₂ H ₂₅ ClN ₈ O |
| Molecular Weight: | 452.94 |
| Target: | CDK |
| Pathway: | Cell Cycle/DNA Damage |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | |
|-------------------------------------|---|-------------------------------------|
| Description | CDK6/9-IN-1 (compound 66) is an orally active active and dual CDK 6 and CDK 9 inhibitor, with IC ₅₀ values of 40.5 nM and 39.5 nM for CDK6 and CDK9, respectively ^[1] . | |
| IC₅₀ & Target | CDK6 40.5 nM (IC ₅₀) | CDK9 39.5 nM (IC ₅₀) |
| In Vitro | CDK6/9-IN-1 (compound 66, 4 or 8 μM in MDA-MB-231 cells) treatment induces G0/G1 cell cycle arrest (71.85% and 77.51%, respectively), when compared with the control (57.65%) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| In Vivo | CDK6/9-IN-1 (compound 66) significantly inhibits tumor growth in an xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |

REFERENCES

[1]. Yang Wang, et al. Discovery and SARs of 5-Chloro- N4-phenyl- N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors With Potent Antitumor Activity. J Med Chem. 2020 Mar 26;63(6):3327-3347.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA